• Quarterly Revenue of $91 million and All-Time High Total Members of 1.1 million
  • Revenue Grew 34% and Total Members Increased 36% Year over Year
  • Raises Full Year 2026 Financial Outlook

SAN FRANCISCO, Nov. 05, 2026 (GLOBE NEWSWIRE) — Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2026.

Financial Highlights

  • Revenue of $91 million, compared with total revenue of $68 million in Q3 2025
  • Gross margin of 76% in the third quarter, up from 66% in Q3 2025
  • Non-GAAP gross margin of 78% in the third quarter, up from 68% in Q3 2025
  • Net income of $7 million in the third quarter, compared with a net loss of $3 million in Q3 2025
  • Adjusted EBITDA of $12 million in the third quarter, compared with Adjusted EBITDA of $2 million in Q3 2025
  • Trailing 12-month revenue per Total Member grew approximately 5% year over year to $294
  • Cash and cash equivalents of $243 million

Please see the non-GAAP Financial Measures section below and reconciliations of GAAP to non-GAAP measures at the end of this press release.

Operational Highlights

  • Total Members reached 1.1 million, increasing 36% year over year, reflecting continued demand across Omada Health’s integrated cardiometabolic care platform and strong enrollment momentum across diabetes and hypertension programs.
  • Average member tenure grew 10% year over year to approximately 2 years and 4 months, which is roughly an additional 2.5 months in program.

“Omada Health delivered its strongest quarter yet, with revenue growing 34% year over year, Total Members increasing 36% and a GAAP gross margin of 76%,” said Sean Duffy, co-founder and CEO of Omada Health. “Our diabetes and hypertension programs led that growth, and average tenure in our programs reached a record of roughly two years and four months. That gives members more time to build lasting habits and the confidence to manage their health.”

Financial Outlook

For the year ending December 31, 2026, Omada Health expects:

  • Revenue in the range of $344 million to $346 million, up from prior guidance of $334 million to $340 million, with the midpoint representing approximately 33% growth compared with 2025.
  • Adjusted EBITDA in the range of $32 million to $34 million, up from prior guidance of $21 million to $27 million, with the midpoint representing an improvement of approximately $27 million, or roughly five and a half times, compared with 2025.

We have not provided an outlook for net income (loss) (GAAP) or a reconciliation of expected Adjusted EBITDA to net income (loss) (GAAP) because net income (loss) (GAAP) on a forward-looking basis is not available without unreasonable effort due to the potential variability and complexity of the items that are excluded from Adjusted EBITDA, such as loss on debt extinguishment; provision for income taxes; depreciation and amortization; share-based compensation; change in fair value of warrant liabilities; amortization of intangible assets; and loss on disposal of property and equipment.

Conference Call
Omada Health will host a conference call at 1:30 p.m. PT/4:30 p.m. ET today, November 5, 2026, during which management will discuss third quarter 2026 results.

A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months.

Those participating via conference call can preregister using the following link:
https://register-conf.media-server.com/register/BIcb6fa0e5bd8d4b91a30bc5b4de7e5fb8 

About Omada Health
Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today’s healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada Health’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada Health has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements contained in this press release include, but are not limited to, statements we make regarding our ability to deliver profitable growth, business trends, growth prospects and future financial and operating results, and our financial outlook.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions and other factors. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, but are not limited to, the following: our limited operating history and ability to manage our growth effectively; our history of net losses and ability to maintain profitability; the ability of our programs to achieve and maintain market acceptance; changes in the healthcare industry and competition; the growth and success of our customers and channel partners; the number of individuals covered by our programs and the number of our programs covered by our customers; the level of member engagement in our programs; our ability to maintain and grow customer and channel partner relationships; concentration of a substantial portion of our sales among a limited number of customers and channel partners; our ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners; our ability to increase the size of our organization; our dependence on a limited number of third-party suppliers; the impact of seasonality on our financial results; our ability to achieve widespread brand awareness and the impact of any negative media coverage; our ability to develop and release new programs and services; cybersecurity threats; our dependence on the interoperability of our programs and connected devices with third-party devices, operating systems and applications; economic uncertainties or downturns in the general economy or the industries in which we or our customers or channel partners operate; changes in laws or regulations or the implementation of existing laws and regulations; compliance with privacy and security laws and regulations; our and our affiliated professional entities’ compliance with healthcare regulatory laws; any modification in U.S. Food and Drug Administration enforcement policies; our dependence on our relationships with affiliated professional entities; and other risk factors identified in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which is being filed at or around the date hereof.

All forward-looking statements in this press release are based only on information currently available to us and speak only as of the date on which they are made. We undertake no obligation to publicly update, revise, or correct any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required under applicable law.

Investor Relations Contact:
Craig Gracey
ir@omadahealth.com 

Media Contact:
Rose Ramseth
press@omadahealth.com 

Omada Health, Inc.
Consolidated Balance Sheets
(in thousands, except per-share amounts)
(unaudited)
 
  September 30,
2026
  December 31,
2025
Assets      
Current assets      
Cash and cash equivalents $  243,151      $  222,036   
Accounts receivable, net (1)    48,193         34,585   
Inventory    4,880         4,486   
Deferred commissions, current    3,951         3,539   
Prepaid expenses and other current assets (2)    14,887         8,288   
Total current assets    315,062         272,934   
Property and equipment, net    9,738         7,942   
Deferred commissions, non-current    8,984         8,711   
Intangible assets, net    1,097         2,414   
Goodwill    13,240         13,240   
Other assets    417         165   
Total assets $  348,538      $  305,406   
       
Liabilities and stockholders’ equity      
Current liabilities      
Accounts payable (3) $  8,385      $  10,276   
Accrued expenses and other current liabilities (4)    41,159         40,392   
Deferred revenue (5)    25,835         25,058   
Total current liabilities    75,379         75,726   
Other liabilities, non-current    –         –   
Total liabilities    75,379         75,726   
Commitments and contingencies      
Stockholders’ equity      
Common stock, $0.001 par value per share; 750,000 and 750,000 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 61,996 and 58,429 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively    62         58   
Additional paid-in capital    720,966         686,366   
Accumulated deficit    (447,869 )      (456,744 )
Total stockholders’ equity    273,159         229,680   
Total liabilities and stockholders’ equity $  348,538      $  305,406   

 

(1) Includes amounts from a related party of $29.0 million and $22.8 million as of September 30, 2026 and December 31, 2025, respectively.
(2) Includes amounts from a related party of $0.4 million and $0.3 million as of September 30, 2026 and December 31, 2025, respectively.
(3) Includes amounts from a related party of $1.1 million and $1.0 million as of September 30, 2026 and December 31, 2025, respectively.
(4) Includes amounts from a related party of $4.2 million and $4.9 million as of September 30, 2026 and December 31, 2025, respectively.
(5) Includes amounts from a related party of $19.2 million and $18.8 million as of September 30, 2026 and December 31, 2025, respectively. 

 

Omada Health, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per-share data)
(unaudited)
 
  Three Months Ended September 30,   Nine Months Ended September 30,
2026   2025   2026   2025
Revenue              
Services (1) $ 85,106     $ 62,936     $ 235,392     $ 169,392  
Hardware (2)   6,200       5,094       21,797       14,972  
Total revenue   91,306       68,030       257,189       184,364  
Cost of revenue              
Services (3)   13,174       12,654       41,232       38,071  
Hardware   8,850       10,305       34,195       29,016  
Total cost of revenue   22,024       22,959       75,427       67,087  
Gross profit   69,282       45,071       181,762       117,277  
Operating expenses              
Research and development (4)   15,271       10,301       42,593       29,131  
Sales and marketing (5)   29,107       22,943       85,782       65,431  
General and administrative (6)   20,084       14,340       49,799       37,968  
Total operating expenses   64,462       47,584       178,174       132,530  
Operating income (loss)   4,820       (2,513 )     3,588       (15,253 )
Other income (expense), net              
Interest expense   (262 )     (353 )     (294 )     (2,521 )
Interest income   1,993       2,009       5,581       3,414  
Loss on debt extinguishment   –       (2,109 )     –       (2,109 )
Change in fair value of warrant liabilities   –       (212 )     –       (1,468 )
Total other income (expense), net   1,731       (665 )     5,287       (2,684 )
Income (loss) before provision for income taxes   6,551       (3,178 )     8,875       (17,937 )
Provision for income taxes   –       –       –       –  
Net income (loss) and comprehensive income (loss) $ 6,551     $ (3,178 )   $ 8,875     $ (17,937 )
               
Net income (loss) per share              
Basic $  0.11      $  (0.06 )   $  0.15      $  (0.61 )
Diluted $  0.10      $  (0.06 )   $  0.14      $  (0.61 )
               
Weighted-average shares outstanding              
Basic   61,499       57,658       60,045       29,421  
Diluted   67,121       57,658       64,561       29,421  

 

(1) Includes amounts from a related party of $53.7 million and $41.8 million for the three months ended September 30, 2026 and 2025, respectively and $151.1 million and $108.2 million for the nine months ended September 30, 2026 and 2025, respectively.
(2) Includes amounts from a related party of $4.0 million and $3.0 million for the three months ended September 30, 2026 and 2025, respectively and $13.9 million and $9.0 million for the nine months ended September 30, 2026 and 2025, respectively.
(3) Includes amounts from a related party of $1.4 million and $1.4 million for the three months ended September 30, 2026 and 2025, respectively and $4.1 million and $3.8 million for the nine months ended September 30, 2026 and 2025, respectively.
(4) Includes amounts from a related party of $0.9 million and $0.6 million for the three months ended September 30, 2026 and 2025, respectively and $2.4 million and $1.6 million for the nine months ended September 30, 2026 and 2025, respectively.
(5) Includes amounts from a related party of $8.7 million and $7.1 million for the three months ended September 30, 2026 and 2025, respectively and $25.6 million and $19.3 million for the nine months ended September 30, 2026 and 2025, respectively.
(6) Includes amounts from a related party of $0.4 million and $0.4 million for the three months ended September 30, 2026 and 2025, respectively and $1.4 million and $1.1 million for the nine months ended September 30, 2026 and 2025, respectively.

 

Omada Health, Inc.
Share-based Compensation Summary
(in thousands)
(unaudited)
 
  Three Months Ended September 30,   Nine Months Ended September 30,
  2026   2025   2026   2025
Services cost of revenue $ 121   $ 33   $ 284   $ 104
Research and development $ 1,053     611   $ 2,784     1,634
Sales and marketing $ 2,058     1,049   $ 5,534     2,663
General and administrative $ 2,619     1,843   $ 7,089     4,809
Total share-based compensation expense $ 5,851   $ 3,536   $ 15,691   $ 9,210

 

Omada Health, Inc.
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
 
  Nine Months Ended September 30,
  2026   2025
Operating activities      
Net income (loss) $ 8,875     $ (17,937 )
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities      
Depreciation and amortization   4,770       4,044  
Share-based compensation   15,691       9,210  
Loss on debt extinguishment   –       2,109  
Loss on disposal of property and equipment   54       2  
Amortization of debt issuance costs   –       285  
Non-cash operating lease expense   –       447  
Change in fair value of warrant liabilities   –       1,468  
Provision for credit losses (1)   2,316       1,485  
Amortization of deferred commissions   2,898       2,467  
Changes in operating assets and liabilities      
Accounts receivable (2)   (15,924 )     (19,514 )
Inventory   (394 )     148  
Prepaid expenses and other current assets (3)   (6,599 )     (1,570 )
Deferred commissions   (3,583 )     (2,319 )
Other non-current assets   (252 )     181  
Accounts payable (4)   (2,083 )     1,373  
Operating lease liabilities   –       (415 )
Accrued expenses and other current liabilities (5)   767       7,782  
Deferred revenue (6)   777       7,627  
Other non-current liabilities   –       –  
Net cash provided by (used in) operating activities   7,313       (3,127 )
       
Investing activities      
Purchases of property and equipment   (342 )     (1,123 )
Capitalized internal-use software costs   (4,512 )     (3,363 )
Net cash used in investing activities   (4,854 )     (4,486 )
       
Financing activities      
Proceeds from exercise of stock options   19,984       5,993  
Taxes paid related to net share settlement of equity awards   (1,328 )     –  
Payment of deferred offering costs   –       (4,284 )
Repayment of debt principal   –       (30,963 )
Payment of debt extinguishment costs   –       (1,430 )
Proceeds from initial public offering, net of underwriting discounts and commissions   –       160,532  
Net cash provided by financing activities   18,656       129,848  
       
Net increase in cash and cash equivalents   21,115       122,235  
Cash and cash equivalents at beginning of period   222,036       76,392  
Cash and cash equivalents at end of period $ 243,151     $ 198,627  

 

(1) Includes changes in related party balances of $1.4 million and $0.5 million for the nine months ended September 30, 2026 and 2025, respectively.
(2) Includes changes in related party balances of $7.7 million and $15.6 million for the nine months ended September 30, 2026 and 2025, respectively.
(3) Includes changes in related party balances of less than $0.1 million and $0 for the nine months ended September 30, 2026 and 2025, respectively.
(4) Includes changes in related party balances of $0.1 million and $0 for the nine months ended September 30, 2026 and 2025, respectively.
(5) Includes changes in related party balances of $0.7 million and $3.0 million for the nine months ended September 30, 2026 and 2025, respectively.
(6) Includes changes in related party balances of $0.4 million and $7.1 million for the nine months ended September 30, 2026 and 2025, respectively.

Non-GAAP Financial Measures

We use certain financial measures not calculated in accordance with accounting principles generally accepted in the United States (“GAAP”) to supplement the financial information in our consolidated financial statements, which are presented in accordance with GAAP. These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, adjusted EBITDA, adjusted EBITDA margin, and free cash flow.

We define non-GAAP gross profit and non-GAAP gross margin as gross profit and gross margin, excluding share-based compensation expense, amortization of intangible assets, and depreciation and amortization.

We define adjusted EBITDA as net income (loss) and comprehensive income (loss) reported on our consolidated statements of operations, excluding the impact of interest expense, interest income, change in fair value of warrant liabilities, loss on debt extinguishment, provision for income taxes, share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment.

Free cash flow is net cash provided by (used in) operating activities less purchases of property and equipment and capitalized internal-use software costs.

We believe these non-GAAP financial measures, when taken collectively with GAAP financial information, are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making. However, there are a number of limitations related to the use of non-GAAP financial measures. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Metric

Total Members: A member is a person who is enrolled in one of our virtual care programs and that generated a billing event in the preceding 12 months. We believe growth in the number of members is a key indicator of the performance of our business for both investors and management as we monitor the performance of our business, as members primarily drive services revenue. The number of members depends, in part, on our ability to successfully market our services to new customers and channel partners, our ability to sell additional programs to existing customers and channel partners, and our ability to promote awareness of our programs among covered individuals and to encourage their enrollment.

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile to the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

 

Omada Health, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures – Adjusted EBITDA
(in thousands)
(unaudited)
 
  Three Months Ended September 30,   Nine Months Ended September 30,
  2026   2025   2026   2025
  (in thousands, except percentages)
GAAP net income (loss) and comprehensive income (loss) $ 6,551     $ (3,178 )   $ 8,875     $ (17,937 )
Add:              
Interest expense   262       353       294       2,521  
Interest income   (1,993 )     (2,009 )     (5,581 )     (3,414 )
Change in fair value of warrant liabilities   —       212       —       1,468  
Loss on debt extinguishment   —       2,109       —       2,109  
Provision for income taxes   —       —       —       —  
Share-based compensation expense   5,851       3,536       15,691       9,210  
Amortization of intangible assets   439       439       1,317       1,411  
Depreciation and amortization(1)   1,242       920       3,453       2,633  
Loss on disposal of property and equipment   27       1       54       3  
Adjusted EBITDA $ 12,379     $ 2,383     $ 24,103     $ (1,996 )
GAAP net income (loss) and comprehensive income (loss) margin (as a percentage of revenue)   7 %     (5 )%     3 %     (10 )%
Adjusted EBITDA margin (as a percentage of revenue)   14 %     4 %     9 %     (1 )%

 

(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

 

Omada Health, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands)
(unaudited)
 
  Three Months Ended September 30,   Nine Months Ended September 30,
  2026   2025   2026   2025
  (in thousands, except percentages)
GAAP gross profit $ 69,282     $ 45,071     $ 181,762     $ 117,277  
Add:              
Share-based compensation expense   121       33       284       104  
Amortization of intangible assets   439       439       1,317       1,317  
Depreciation and amortization(1)   1,138       839       3,169       2,366  
Non-GAAP gross profit   70,980       46,382       186,532       121,064  
GAAP gross margin (as a percentage of revenue)   76 %     66 %     71 %     64 %
Non-GAAP gross margin (as a percentage of revenue)   78 %     68 %     73 %     66 %

 

(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

 

GAAP Research and development expense $ 15,271     $ 10,301     $ 42,593     $ 29,131  
Less:              
Share-based compensation expense   1,053       611       2,784       1,634  
Depreciation and amortization (1)   38       23       103       61  
Non-GAAP research and development expense $ 14,180     $ 9,667     $ 39,706     $ 27,436  
Non-GAAP research and development expense (as a % of revenue)   16 %     14 %     15 %     15 %
               
GAAP Sales and marketing expense $ 29,107     $ 22,943     $ 85,782     $ 65,431  
Less:              
Share-based compensation expense   2,058       1,049       5,534       2,663  
Amortization of intangible assets   —       —       —       94  
Depreciation and amortization (1)   40       31       112       87  
Non-GAAP sales and marketing expense $ 27,009     $ 21,863     $ 80,136     $ 62,587  
Non-GAAP sales and marketing expense (as a % of revenue)   30 %     32 %     31 %     34 %
               
GAAP General and administrative expense $ 20,084     $ 14,340     $ 49,799     $ 37,968  
Less:              
Share-based compensation expense   2,619       1,843       7,089       4,809  
Depreciation and amortization (1)   26       27       69       119  
Loss on disposal of property and equipment   27       1       54       3  
Non-GAAP general and administrative expense $ 17,412     $ 12,469     $ 42,587     $ 33,037  
Non-GAAP general and administrative expense (as a % of revenue)   19 %     18 %     17 %     18 %
               
GAAP operating expenses $ 64,462     $ 47,584     $ 178,174     $ 132,530  
Less:              
Share-based compensation expense   5,730       3,503       15,407       9,106  
Amortization of intangible assets   —       —       —       94  
Depreciation and amortization(1)   104       81       284       267  
Loss on disposal of property and equipment   27       1       54       3  
Non-GAAP operating expenses $ 58,601     $ 43,999     $ 162,429     $ 123,060  
GAAP operating expenses margin (as a percentage of revenue)   71 %     70 %     69 %     72 %
Non-GAAP operating expenses margin (as a percentage of revenue)   64 %     65 %     63 %     67 %

 

(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

 

Omada Health, Inc.  
Reconciliation of GAAP Net Cash Provided by (Used in) Operating Activities to Free Cash Flow
(in thousands)      
(unaudited)      
   
  Nine Months Ended September 30,
  2026   2025
Net cash provided by (used in) operating activities $ 7,313     $ (3,127 )
Purchases of property and equipment   (342 )     (1,123 )
Capitalized internal-use software costs   (4,512 )     (3,363 )
Free Cash Flow $ 2,459     $ (7,613 )
Other cash flow components:      
Net cash used in investing activities $ (4,854 )   $ (4,486 )
Net cash provided by financing activities $ 18,656     $ 129,848  

 


Primary Logo

Media gallery

About The Author